<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer : an international multicenter study</dc:title><dc:creator>Megyesfalvi,	Zsolt	(Avtor)
	</dc:creator><dc:creator>Barany,	Nandor	(Avtor)
	</dc:creator><dc:creator>Lantos,	Andras	(Avtor)
	</dc:creator><dc:creator>Valko,	Zsuzsanna	(Avtor)
	</dc:creator><dc:creator>Pipek,	Orsolya	(Avtor)
	</dc:creator><dc:creator>Lang,	Christian	(Avtor)
	</dc:creator><dc:creator>Schwendenwein,	Anna	(Avtor)
	</dc:creator><dc:creator>Oberndorfer,	Felicitas	(Avtor)
	</dc:creator><dc:creator>Paku,	Sandor	(Avtor)
	</dc:creator><dc:creator>Ferencz,	Bence	(Avtor)
	</dc:creator><dc:creator>Kern,	Izidor	(Avtor)
	</dc:creator><dc:creator>Kovačević,	Mile	(Avtor)
	</dc:creator><dc:creator>Laszlo,	Viktoria	(Avtor)
	</dc:creator><dc:creator>Dome,	Balazs	(Avtor)
	</dc:creator><dc:subject>Non-small-cell lung carcinoma</dc:subject><dc:subject>immunohistochemistry</dc:subject><dc:subject>molecular subtypes</dc:subject><dc:subject>prognostic relevance</dc:subject><dc:subject>expression pattern</dc:subject><dc:subject>neuroendocrine subtypes</dc:subject><dc:description>The tissue distribution and prognostic relevance of subtype-specific proteins (ASCL1, NEUROD1, POU2F3, YAP1) present an evolving area of research in small cell lung cancer (SCLC). The expression of subtype-specific transcription factors and P53 and RB1 proteins were measured by immunohistochemistry (IHC) in 386 surgically resected SCLC samples. Correlations between subtype-specific proteins and in vitro efficacy of various therapeutic agents were investigated by proteomics and cell viability assays in 26 human SCLC cell lines. Besides SCLC-A (ASCL1-dominant), SCLC-AN (combined ASCL1/NEUROD1), SCLC-N (NEUROD1-dominant) and SCLC-P (POU2F3-dominant), IHC and cluster analyses identified a quadruple-negative SCLC subtype (SCLC-QN). No unique YAP1-subtype was found. The highest overall survival rates were associated with non-neuroendocrine subtypes (SCLC-P and SCLC-QN) and the lowest with neuroendocrine subtypes (SCLC-A, SCLC-N, SCLC-AN). In univariate analyses, high ASCL1 expression was associated with poor prognosis and high POU2F3 expression with good prognosis. Notably, high ASCL1 expression influenced survival outcomes independently of other variables in a multivariate model. High POU2F3 and YAP1 protein abundances correlated with sensitivity and resistance to standard-of-care chemotherapeutics, respectively. Specific correlation patterns were also found between the efficacy of targeted agents and subtype-specific protein abundances. In conclusion, we have investigated the clinicopathological relevance of SCLC molecular subtypes in a large cohort of surgically resected specimens. Differential IHC expression of ASCL1, NEUROD1 and POU2F3 defines SCLC subtypes. No YAP1-subtype can be distinguished by IHC. High POU2F3 expression is associated with improved survival in a univariate analysis, whereas elevated ASCL1 expression is an independent negative prognosticator. Proteomic and cell viability assays of human SCLC cell lines reveal distinct vulnerability profiles defined by transcription regulators.</dc:description><dc:publisher>John Wiley &amp;Sons</dc:publisher><dc:date>2022</dc:date><dc:date>2022-05-27 12:59:24</dc:date><dc:type>Neznano</dc:type><dc:identifier>15120</dc:identifier><dc:identifier>UDK: 616</dc:identifier><dc:identifier>ISSN pri članku: 1096-9896</dc:identifier><dc:identifier>DOI: 10.1002/path.5910</dc:identifier><dc:identifier>COBISS_ID: 107358467</dc:identifier><dc:language>sl</dc:language><dc:rights>© 2022 The Authors.</dc:rights></metadata>
